Pure Global AI
NCT04478097Not yet recruiting

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D086 in Healthy Volunteers Under Fasting Conditions
Chong Kun Dang PharmaceuticalPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Cardiovascular Disease
Drug/Device/Intervention
CKD-330 Tab. and D086 Tab.
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chong Kun Dang Pharmaceutical
Location
Daejeon, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
Jul 14, 2020
End date
Jan 01, 2021
Enrollment
51 participants
Primary outcome

AUCt of CKD-330, D086, CKD-333,Cmax of CKD-330, D086, CKD-333

Summary

This study is a randomized, open, single-dose, 3 period partial replicated crossover-design
 study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy
 volunteers.

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04478097
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04478097 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chong Kun Dang Pharmaceutical and is currently Not yet recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 51 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.